MétaCan
Menu
← Back to cohort
Record W4409435797 · doi:10.3390/curroncol32040225

A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening

2025· review· en· W4409435797 on OpenAlexaffvenue
Diedron Lewis, Laura Jiménez, Kelvin Chan, Susan Horton, William Wong

Bibliographic record

VenueCurrent Oncology · 2025
Typereview
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsHealth Sciences CentreSunnybrook Health Science CentreDalhousie UniversityUniversity of Waterloo
Fundersnot available
KeywordsMedicineScopusColorectal cancerFamilial adenomatous polyposisPancreatic cancerCost effectivenessSystematic reviewInclusion and exclusion criteriaMEDLINECancerFamily medicineInternal medicineAlternative medicinePathologyRisk analysis (engineering)

Abstract

fetched live from OpenAlex

BACKGROUND: Pancreatic cancer (PC) is among the deadliest types of cancer globally. While early detection helps avert adverse outcomes, screening is only recommended for individuals at high risk, specifically those with familial and/or genetic predispositions. The objectives of this study are to systematically review primary studies on the cost-effectiveness of PC screening and to identify the critical factors that influence cost-effectiveness. METHODS: This systematic review was performed using PRISMA guidelines. Economic evaluation studies on PC screening were identified from searches on the SCOPUS and PubMed databases. The quality of reporting of the selected articles was assessed according to CHEERS 2022. Using predefined inclusion and exclusion criteria, two reviewers conducted the title-abstract review, full-text review, and data extraction to select relevant articles. The authors' consensus was used to settle disagreements. The primary outcome was the incremental cost-effectiveness ratio, measured by cost per quality-adjusted life year and cost per life year saved. RESULTS: Nine studies were selected for the final review. Most studies demonstrated that one-time screening for PC among high-risk individuals was cost-effective compared with no screening, while others found annual screening to also be cost-effective. High-risk was generally defined as having a >5% lifetime risk of PC and included individuals with either familial pancreatic cancer (FPC) or genetic susceptibility syndromes such as Peutz-Jeghers Syndrome, hereditary pancreatitis, hereditary non-polypoid colorectal cancer syndrome, familial adenomatous polyposis, and BRCA2 mutations. Individuals with new-onset diabetes (NOD) were also considered high-risk. Screening using mainly endoscopic ultrasound was cost-effective among FPC individuals and those with genetic syndromes. Risk-based screening was also cost-effective among patients with NOD. CONCLUSION: Screening for PC is cost-effective among selected high-risk individuals. However, cost-effectiveness depends on epidemiological factors, cost, the diagnostic performance of screening tools, and the overall design of studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.023
metaresearch head score (Gemma)0.110
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.023
Threshold uncertainty score0.121

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0230.110
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0140.018
Bibliometrics0.0160.015
Science and technology studies0.0010.001
Scholarly communication0.0050.003
Open science0.0030.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.417
GPT teacher head0.603
Teacher spread0.185 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueCurrent Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→